Delivering Next Generation Regenerative Medicine
Tuesday 13 January 2026
1:30 PM GMT (UTC +0)
Virtual Thought Leadership Session held on Zoom
AGENDA OVERVIEW
1.30pm Thought Leader Interview with Professor Dame Molly Stevens
2.00pm Panel Discussion: Delivering Next-Generation Regenerative Medicine Through Bioengineering
- Translating nanoscale and bioactive scaffold innovations from lab to clinic
- Engineering the cell–material interface
- How bioengineered tissues and neurotechnology devices intersect
- Advances in neural tissue engineering
- Conventional clinical approaches to PD
- How emerging devices and bioengineered materials may shift therapeutic paradigms
Panellists
Andrea Serio, Reader in Neural Tissue Engineering, King’s College London & Group Leader, The Francis Crick Institute
Roger Barker, Professor of Clinical Neuroscience, University of Cambridge
George Malliaras, Prince Philip Professor of Technology, University of Cambridge
THOUGHT LEADER & MODERATOR
Biography:
Professor Dame Molly Stevens FREng FRS is John Black Professor of Bionanoscience at the University of Oxford and also holds part-time professorships at Imperial College London and the Karolinska Institute. Molly’s multidisciplinary research balances the investigation of fundamental science with the development of technology to address some of the major healthcare challenges. She is a serial entrepreneur and the founder of several companies in the diagnostics, advanced therapeutics and regenerative medicine space. Her work has been instrumental in elucidating the bio-material interfaces. She has created a broad portfolio of designer biomaterials for applications in disease diagnostics and regenerative medicine. Her substantial body of work influences research groups around the world.
Innovative Contamination Control in Cell Therapy: Enabling Integrity and Efficiency
Sponsored by Thermo Fisher Scientific
Thursday 12 February 2026
3pm GMT
Sponsor Webinar held on Zoom
Presented by George Prout & Suzy Brown
Effective contamination control is essential for maintaining the integrity and quality of cell therapy manufacturing.
This presentation will discuss the use of upstream solutions such as automated closed systems for isolation and activation, and larger bioprocess containers. It will also cover the application of analytical assays for sterility testing, mycoplasma detection, and environmental monitoring.
These measures aim to reduce contamination and improve overall operational effectiveness. An integrated approach combining these solutions can enhance contamination control, boost process efficiency, and ensure the production of high-quality cell therapy products.
SPEAKER BIO
George Prout & Suzy Brown
George Prout is a Senior Application Scientist at Thermo Fisher Scientific covering Cell Culture and Cell Therapy. His role involves technical support with customers wanting to drive higher output of their systems and actively looks for collaborations with fellow scientists in disciplines such as protein production, plasmid production, vaccines, cultured meat, microbial processes, gene therapy and cell therapy from research, to process development and scale-up. George has 8 years of experience in Gene Therapy prior to joining Thermo Fisher Scientific, with a focus on manufacturing, process development and project management.
Suzy Brown is the Senior Field Application Scientist for Pharma Analytics at Thermo Fisher Scientific, supporting customers across the UK and Ireland. With nine years at Thermo Fisher, she leads training and implementation for the Pharma Analytics portfolio and serves as the MycoSEQ subject matter expert for the EMEA region.
Suzy holds a PhD in Developmental Biology and a Bachelor’s degree in Cell Biology from the University of Manchester, where she used molecular, proteomic and next-generation sequencing approaches to identify genes involved in pattern formation using Dictyostelium discoideum. Before joining Thermo Fisher, she worked in the biopharmaceutical industry as an Analytical Development Scientist at Allergan Biologics, gaining hands-on expertise in qPCR, Sanger sequencing and impurity testing.
